News for BeiGene Ltd (spons. ADRs)

TipRanks 285d

Jefferies Sticks to Their Buy Rating for BeiGene (BGNE)

TipRanks 288d

Hold Rating on BeiGene Amid Mixed Drug Performance and Strong Pipeline Potential

TipRanks 292d

BeiGene’s Strong Financial and Clinical Prospects Solidify Buy Rating

TipRanks 292d

BeiGene: A Strong Buy on Robust Brukinsa Sales and Upward Financial Forecasts

TipRanks 293d

BeiGene’s Brukinsa Drives Strong Growth and Justifies Buy Rating

TipRanks 294d

Buy Rating for BeiGene Backed by Brukinsa’s Market Growth and Strong Financial Outlook

Seeking Alpha 294d

BeiGene GAAP ADS of -$1.15 beats by $1.20, revenue of $929.17M beats by $119.98M

Seeking Alpha 314d

BeiGene names Aaron Rosenberg as CFO

TipRanks 323d

BeiGene Analysis: Hold Rating Amidst Mixed Drug Sales Performance and Market Competition

TipRanks 350d

BeiGene Hold Rating Justified by Mixed Sales Performance and Competitive Market Pressures

TipRanks 359d

Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE), Immunocore Holdings (IMCR) and COMPASS Pathways (CMPS)

InvestorPlace 364d

7 Large-Cap Stocks That Can Jump 50% By 2025

Seeking Alpha 365d

BriaCell signs supply agreement with BeiGene for metastatic breast cancer treatment

TipRanks 378d

Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Sanara MedTech (SMTI)

TipRanks 378d

BeiGene Performance Analysis: A Hold Rating with Cautious Optimism Amidst Competitive Pressures

Seeking Alpha 380d

Merck discontinues testing of experimental skin cancer combo therapy

TipRanks 383d

BeiGene’s Soaring Sales and Path to Profitability Reinforce Buy Rating

TipRanks 383d

Buy Rating Affirmed for BeiGene on Strong Q4 Performance and Promising Brukinsa Sales

InvestorPlace 385d

BGNE Stock Earnings: BeiGene Beats EPS, Beats Revenue for Q1 2024

Seeking Alpha 385d

BeiGene GAAP EPADS of -$2.41 beats by $0.48, revenue of $751.65M beats by $76.42M

Markets Insider Automation 386d

BeiGene is about to announce its earnings — here's what Wall Street expects

Seeking Alpha 392d

BeiGene, AbbVie patent spat to get trial from USPTO appeals board

TipRanks 398d

BeiGene (BGNE) Receives a Hold from Bernstein

Benzinga 399d

Evaluating BeiGene: Insights From 6 Financial Analysts

Seeking Alpha 400d

EU regulators approve BeiGene's tislelizumab for lung cancer

TipRanks 415d

Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE), Alcon (ALC) and Teladoc (TDOC)

Benzinga 427d

4 Analysts Assess BeiGene: What You Need To Know

TipRanks 428d

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE) and BeiGene (BGNE)

Benzinga 432d

Lululemon Issues Weak Outlook, Joins Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session

TipRanks 439d

BeiGene: Hold Recommendation Amidst Mixed Financial Indicators and Robust Drug Pipeline Growth

Seeking Alpha 440d

BeiGene gets FDA approval for esophageal cancer drug Tevimbra

Benzinga 441d

Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Seeking Alpha 441d

BeiGene gains as access to leukemia drug Brukinsa expands

Seeking Alpha 441d

KB Financial, BeiGene, Legend Biotech among premarket gainers' pack

Benzinga 441d

Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session

Seeking Alpha 447d

BeiGene gets FDA accelerated approval for Brukinsa for follicular lymphoma

TipRanks 455d

Analysts Are Bullish on These Healthcare Stocks: Athira Pharma (ATHA), BeiGene (BGNE)

TipRanks 455d

Buy Rating Reaffirmed on BeiGene Amid Strong Brukinsa Sales and Strategic Stability

TipRanks 456d

BeiGene Hold Rating Upheld Amid Revenue Growth and Market Challenges

Seeking Alpha 456d

FDA accepts BeiGene license application for gastric cancer combo therapy

TipRanks 456d

BeiGene: Balancing Robust Zanubrutinib Sales and Financial Challenges – A Hold Rating

TipRanks 457d

Brukinsa’s Market Dominance and BeiGene’s Promising Pipeline Fuel Buy Rating and New Price Target

TipRanks 457d

Analysts Are Bullish on Top Healthcare Stocks: BeiGene (BGNE), McKesson (MCK)

Seeking Alpha 457d

BeiGene gets EU backing for lung cancer therapy

Seeking Alpha 457d

BeiGene GAAP EPADS of -$3.53 beats by $0.38, revenue of $634.4M misses by $1.75M

InvestorPlace 470d

Get Rich Quick With These 3 Biotech Stocks to Buy Now

TipRanks 471d

Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), BeiGene (BGNE) and Catalent (CTLT)

Seeking Alpha 476d

I-Mab to divest Chinese assets amid rising geopolitical tensions

InvestorPlace 477d

3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List

Benzinga 477d

JP Morgan's Bullish View On This Chinese Biotech, Says Pullback Creates Entry Point

	
		OSZAR »